Loading...
Loading...
Just when little old Betaville thought the recent biopharmaceutical dealmaking boom might have ended BioMarin Pharmaceutical pops up with a $4.8 billion takeover of Amicus Therapeutics, a US-listed rare metabolic disease drug developer.